Suzuki Ryo, Chand Krishant, Taguchi Yuu
Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Novo Nordisk Pharma Ltd., Tokyo, Japan.
Diabetes Ther. 2025 May 28. doi: 10.1007/s13300-025-01739-2.
The oral formulation of the glucagon-like peptide-1 receptor agonist semaglutide has dosing requirements that could impact adherence. We compared perceptions of physicians and individuals with type 2 diabetes (T2D) in Japan, before and after initiating oral semaglutide, with respect to adherence to dosing requirements.
In this observational study, online questionnaires were completed by treating physicians and adults with T2D who had received either oral semaglutide or other oral antidiabetic medications for ≥ 6 months. Physicians reported the expected adherence of their patients to oral semaglutide and expected patient difficulties around the dosing requirements prior to (baseline) and after (time of survey) initiating oral semaglutide. Patient-reported adherence and difficulties experienced with the dosing requirements were assessed after oral semaglutide was initiated.
Overall, 330 physicians and 412 individuals with T2D responded. There was a statistically significant difference (P < 0.001) between baseline and time of survey in the distribution of physicians who expected that ≥ 80% or < 80% of their patients would adhere to oral semaglutide, with 17.2% of physicians expecting ≥ 80% of their patients to be adherent before treatment initiation versus 44.6% reporting ≥ 80% of their patients to be adherent after treatment initiation. There was also a statistically significant difference (P < 0.001) in the distribution of expected versus reported adherence among individuals who received oral semaglutide. After semaglutide initiation, 95.2% of patients reported missing ≤ 1 dose/week. Before prescribing oral semaglutide, 186 (56.4%) physicians were resistant to it, due to the dosing requirements. After prescribing oral semaglutide, 146 (44.2%) reported their resistance had decreased, whereas only 28 (8.5%) reported increased resistance.
We identified an improvement in physician perceptions of oral semaglutide adherence due to dosing requirements following semaglutide initiation. Our findings suggest that individuals with T2D in Japan are capable of adhering to the dosing requirements of oral semaglutide.
胰高血糖素样肽-1受体激动剂司美格鲁肽的口服制剂有给药要求，这可能会影响依从性。我们比较了日本2型糖尿病（T2D）患者在开始口服司美格鲁肽之前和之后，医生及患者对给药要求依从性的看法。
在这项观察性研究中，接受口服司美格鲁肽或其他口服抗糖尿病药物≥6个月的主治医生和成年T2D患者完成了在线问卷。医生报告了他们的患者在开始口服司美格鲁肽之前（基线）和之后（调查时）对口服司美格鲁肽的预期依从性以及在给药要求方面预期患者会遇到的困难。在开始口服司美格鲁肽后，评估患者报告的依从性和在给药要求方面遇到的困难。
总体而言，330名医生和412名T2D患者做出了回应。预期≥80%或<80%的患者会坚持口服司美格鲁肽的医生分布在基线和调查时存在统计学显著差异（P<0.001），17.2%的医生预期在治疗开始前≥80%的患者会坚持服药，而44.6%的医生报告在治疗开始后≥80%的患者会坚持服药。接受口服司美格鲁肽的个体中，预期依从性与报告的依从性分布也存在统计学显著差异（P<0.001）。开始使用司美格鲁肽后，95.2%的患者报告每周漏服≤1剂。在开具口服司美格鲁肽之前，186名（56.4%）医生因其给药要求而对其有抵触情绪。在开具口服司美格鲁肽之后，146名（44.2%）医生报告他们的抵触情绪有所降低，而只有28名（8.5%）医生报告抵触情绪增加。
我们发现，在开始使用司美格鲁肽后，医生对口服司美格鲁肽因给药要求导致的依从性看法有所改善。我们的研究结果表明，日本的T2D患者能够遵守口服司美格鲁肽的给药要求。
